Open Access<p>Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital<sup>®</sup> Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study</p>
Author(s) -
Aino Fianu Jonasson,
Marie Bixo,
Inger Sundström Poromaa,
Mikael Åström
Publication year - 2020
Publication title -
medical devices
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.482
H-Index - 30
ISSN - 1179-1470
DOI - 10.2147/mder.s265824
Subject(s) - medicine , tolerability , vaginal atrophy , oxytocin , intravaginal administration , vaginal bleeding , adverse effect , anesthesia , surgery , vagina , menopause , pregnancy , biology , genetics
The primary objective was to compare the efficacy of 12 weeks of daily treatment with Aqueous Hypromellose-based vaginal (Vagivital ® ) gel versus Aqueous Hypromellose-based vaginal gel plus 400 IU oxytocin gel in reducing the severity of the most bothersome vulvovaginal atrophy symptoms (MBS: itching, dysuria, bleeding, and pain/discomfort during vaginal sexual activity) observed at baseline. The secondary objectives were to evaluate the other vulvovaginal atrophy symptoms, vaginal pH, superficial squamous cells, and the safety and tolerability of both gels.